You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product menu

Young girl holding an infant
BEXSERO: The only MenB vaccine with real world evidence demonstrated in a broad population[1-3]

BEXSERO has demonstrated an impact in reducing cases of meningococcal disease, helping to protect patients in a real life setting (national and regional immunisation programs).[1-2]

Regional: Canada

96% reduction in incidence[1]

 

National: England

75% reduction in MenB disease[2]

 

BEXSERO regional vaccination program in Saguenay-Lac-Saint-Jean (Quebec, Canada)1

  • From May through December 2014, an estimated 83% of 59,500 residents/individuals aged 2 months to 20 years was immunised in 2014 with BEXSERO in response to a MenB outbreak
  • In the four years following the vaccination campaign, serogroup B incidence fell by 96% from 11.4/100,000 (2006 to 2014) to 0.4/100,000 (2014 to 2018) (p<0.0001) in the targeted age group*
Chart depicting the impact of BEXSERO on MenB incidence

*Note during the assessment period MenB disease also decreased in the other regions where no vaccination took place; the magnitude of that decrease in younger and older age groups was over 50%. Taking into account the decrease in MenB incidence at provincial level, the overall campaign impact in the SLSJ was 86% [95% CI: -2%,98%]. The campaign impact was mostly seen in the target age-group suggesting no herd effect among unvaccinated older adults.

BEXSERO national immunisation program in the United Kingdom2

  • In September 2015, England offered BEXSERO to all infants free of charge, as part of a national immunisation program in the UK
  • In England, 92.5% (average annual birth cohort, approximately 650,000 infants) completed their primary immunisation by their first birthday, and 87.9% completed all 3 doses by 2 years
  • Using national surveillance data in England, it was determined MenB disease in all children fully eligible for vaccination was reduced by 75% (rate ratio: 0.25; 95% CI, 0.19 to 0.36) from September 2015 through August 2018
Chart depicting the impact of BEXSERO on infant MenB after national immunisation program

References

  1. Deceuninck G, Lefebvre B, Tsang R, Betala-Belinga JF, De Serres G, De Wals P. Impact of a mass vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243–4245.
  2. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–317.
  3. Pfizer Ltd. Trumenba. Annex I; Summary of Product Characteristics. EMA; May 2018.

 

All mentioned products are registered in Saudi Arabia. This page may contain promotional content. For full prescribing information or adverse events reporting, please click on the relevant button in the header or footer of this page

PM-SA-BEX-WCNT-200006 Date of preparation: September 2020